| 2.12 0.17 (8.72%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.54 |
1-year : | 2.96 |
| Resists | First : | 2.17 |
Second : | 2.54 |
| Pivot price | 1.91 |
|||
| Supports | First : | 1.87 |
Second : | 1.68 |
| MAs | MA(5) : | 1.98 |
MA(20) : | 1.91 |
| MA(100) : | 1.75 |
MA(250) : | 1.72 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 77.4 |
D(3) : | 74.9 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 3.53 | Low : | 0.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRBU ] has closed Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.18 - 2.19 | 2.19 - 2.19 |
| Low: | 1.95 - 1.96 | 1.96 - 1.97 |
| Close: | 2.1 - 2.12 | 2.12 - 2.13 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Fri, 10 Apr 2026
Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan
Fri, 10 Apr 2026
CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Fri, 10 Apr 2026
CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
Tue, 31 Mar 2026
FDA gives advanced therapy status to Caribou's myeloma CAR-T - Stock Titan
Tue, 31 Mar 2026
Caribou rises on FDA RMAT designation (CRBU:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 37.7 (%) |
| Shares Short | 7,060 (K) |
| Shares Short P.Month | 7,770 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.27 |
| Profit Margin | 0 % |
| Operating Margin | -722 % |
| Return on Assets (ttm) | -34.3 % |
| Return on Equity (ttm) | -79 % |
| Qtrly Rev. Growth | 89.6 % |
| Gross Profit (p.s.) | -1 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.65 |
| Price to Sales | 18.35 |
| Price to Cash Flow | -1.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|